Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant

被引:37
|
作者
Eroglu, Celalettin [1 ]
Pala, Cigdem [2 ]
Kaynar, Leylagul [2 ]
Yaray, Kadir [1 ]
Aksozen, M. Tarkan [1 ]
Bankir, Mehmet [2 ]
Zararsiz, Gokmen [3 ]
Orhan, Okan [1 ]
Gundog, Mete [1 ]
Yildiz, Oguz G. [1 ]
Eser, Bulent [2 ]
Cetin, Mustafa [2 ]
Unal, Ali [2 ]
机构
[1] Erciyes Univ, Dept Radiat Oncol, Fac Med, Kayseri, Turkey
[2] Erciyes Univ, Dedeman Stem Cell Transplantat Hosp, Fac Med, Dept Hematol, Kayseri, Turkey
[3] Erciyes Univ, Dept Biostat & Med Informat, Fac Med, Kayseri, Turkey
关键词
TBI plus Cy; Bu plus Cy; conditioning regimen; ALL; BONE-MARROW-TRANSPLANTATION; ADULT PATIENTS; 1ST;
D O I
10.3109/10428194.2013.779691
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Conditioning regimens used during stem cell transplant provide prolonged control or cure of the disease in patients with acute lymphoblastic leukemia (ALL). In this study, we present a comparison of treatment results for 95 patients with ALL who underwent allogeneic hematopoietic stem cell transplant (AHSCT) with total body irradiation plus cyclophosphamide (TBI + Cy) or busulfan plus cyclophosphamide (Bu + Cy) as conditioning regimen. Median age was 25 (range: 9-54) years. Median follow-up was 24 (range: 3-107) months. Median overall survival (OS) was found to be 29 months. Median event-free survival (EFS) was 9 months. Median OS was 37 months in the TBI + Cy arm, while it was 12 months in the Bu + Cy arm, suggesting a significant advantage favoring the TBI + Cy arm (p = 0.003). Median EFS was 13 months in the TBI + Cy arm, while it was 4 months in the Bu + Cy arm, indicating a significant difference (p = 0.006). In univariate and multivariate analysis, it was found that high OS and EFS were significantly correlated with TBI + Cy conditioning regimen and lack of transplant-related mortality (p + 0.05). The TBI + Cy conditioning regimen was found to be superior to the Bu + Cy regimen in patients with ALL undergoing AHSCT regarding both OS and EFS.
引用
收藏
页码:2474 / 2479
页数:6
相关论文
共 50 条
  • [21] Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia
    Hirabayashi, N
    Goto, S
    Ishii, M
    Yuge, M
    Mitsuma, A
    Noda, N
    BONE MARROW TRANSPLANTATION, 1998, 21 (11) : 1079 - 1083
  • [22] Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia
    N Hirabayashi
    S Goto
    M Ishii
    M Yuge
    A Mitsuma
    N Noda
    Bone Marrow Transplantation, 1998, 21 : 1079 - 1083
  • [23] Comparison of BuCy (Busulfan plus Cyclophosphamide) Versus FluBu4 (Fludarabine plus Busulfan) As a Conditioning Regimen for Allogeneic Stem Cell Transplantation
    Park, Silvia
    Hong, Jung Yong
    Choi, Moon Ki
    Kim, Young Saing
    Lee, Ji Yun
    Lim, Sung Hee
    Jung, Chul Won
    Jang, Jun Ho
    Kim, Kihyun
    BLOOD, 2012, 120 (21)
  • [24] Outcome of stem cell transplantation for pediatric acute lymphoblastic leukemia. A comparison of cyclophosphamide and total body irradiation versus VP16 and total body irradiation conditioning regimens.
    Gassas, A
    Sung, L
    Saunders, F
    Doyle, J
    BLOOD, 2004, 104 (11) : 32A - 33A
  • [25] Allogeneic Hematopoietic Stem Cell Transplantation Using An Intravenous Busulfan Based Myeloablative Conditioning without Total Body Irradiation for Pediatric Patients with Acute Lymphoblastic Leukemia
    Goussetis, Eugene
    Paisiou, Anna
    Peristeri, Ioulia
    Kitra, Vassiliki
    Vessalas, George
    Dimopoulou, Maria N.
    Baltathakis, Ioannis
    Graphakos, Stelios
    BLOOD, 2010, 116 (21) : 1459 - 1459
  • [26] Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation
    Hickey, Cindy Lynn
    Kim, Haesook T.
    Ho, Vincent T.
    Nikiforow, Sarah
    Gooptu, Mahasweta
    Koreth, John
    Ritz, Jerome
    Romee, Rizwan
    Alyea, Edwin P., III
    Soiffer, Robert J.
    Antin, Joseph H.
    Cutler, Corey
    BLOOD, 2019, 134
  • [27] Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia
    Mora, Elvira
    Montoro, Juan
    Balaguer, Aitana
    Rovira, Montserrat
    Cabrero, Monica
    Heras, Inmaculada
    Ribera, Josep-Maria
    Antelo, Gabriela
    Martin, Ana Africa
    Godino, Oriana Lopez
    Torrent, Anna
    Villalba, Marta
    Chorao, Pedro
    Sanz, Miguel A.
    Sanz, Jaime
    BONE MARROW TRANSPLANTATION, 2024, 59 (08) : 1137 - 1145
  • [28] Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients
    Kröger, N
    Zabelina, T
    Krüger, W
    Renges, H
    Stute, N
    Kabisch, H
    Jaburg, N
    Löliger, C
    Krüll, A
    Zander, AR
    BONE MARROW TRANSPLANTATION, 2001, 27 (04) : 349 - 354
  • [29] Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen-A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    Nagler, Arnon
    Rocha, Vanderson
    Labopin, Myriam
    Unal, Ali
    Ben Othman, Tarek
    Campos, Antonio
    Volin, Liisa
    Poire, Xavier
    Aljurf, Mahmoud
    Masszi, Tamas
    Socie, Gerard
    Sengelov, Henrik
    Michallet, Mauricette
    Passweg, Jakob
    Veelken, Hendrik
    Yakoub-Agha, Ibrahim
    Shimoni, Avichai
    Mohty, Mohamad
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3549 - +
  • [30] Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients
    N Kröger
    T Zabelina
    W Krüger
    H Renges
    N Stute
    H Kabisch
    N Jaburg
    C Löliger
    A Krüll
    AR Zander
    Bone Marrow Transplantation, 2001, 27 : 349 - 354